Albinism 

  • Author: Mounir Bashour, MD, CM, FRCS(C), PhD, FACS; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Feb 11, 2010
 

Background

Albinism consists of a group of inherited abnormalities of melanin synthesis and are typically characterized by a congenital reduction or absence of melanin pigment. Albinism results from defective production of melanin from tyrosine through a complex pathway of metabolic reactions.

Several types of albinism are recognized. The phenotypic heterogeneity of albinism is due to the different gene mutations affecting various points along the melanin pathway, resulting in varying degrees of decreased melanin production. Additionally, associated developmental changes occur in the optic system as a result from this hypopigmentation.

The ophthalmologist plays an important role in detecting albinism because most forms of albinism present with ocular features as the primary morbidity. The changes to the optic system associated with hypopigmentation include decreased visual acuity secondary to foveal hypoplasia and misrouting of the optic nerves at the chiasm. Other features include photophobia, iris transillumination, nystagmus, and pigment deficiency in the peripheral retina. These ocular changes are common to all types of albinism.

Classification of albinism

Traditionally, albinism has been classified according to clinical phenotype, and the 2 main categories are oculocutaneous albinism (OCA) and ocular albinism (OA).

The albinism subtypes were reclassified in 2009. With the availability of new molecular genetic studies, the classification of albinism has shifted emphasis to genotype as opposed to phenotype alone.[1] Hence, this has led to redefining existing phenotypic categories and the addition of new subtypes based on specific genetic mutations. The following is a brief overview of the current classification of albinism.

OCA is characterized by the reduction or absence of melanin in the skin, hair, and optic system (including the eyes and optic nerves). The lack of skin pigment results in a pale skin appearance and an increased risk of skin cancer. As shown in Table 1, OCA is divided further into several subtypes based on the distinct genetic mutation.

Table 1. Oculocutaneous Albinism Types (Open Table in a new window)

OCA SubtypesGene PositionAffected Protein
OCA 1
  • OCA 1A (tyrosinase-negative OCA)
  • OCA 1B (yellow-mutant/Amish/
  • xanthous, temperature-sensitive)
  • OCA 1A/1B heterozygote
11q14-21Tyrosinase
OCA 2



(tyrosinase-positive OCA, brown OCA)



15q11-13P protein
OCA 39p23Tyrosinase-related protein

OA is characterized by changes in the optic system only with no clinical difference in skin and hair color. As shown in Table 2, two major disorders exist in this category, ocular albinism 1 (OA 1) and autosomal recessive ocular albinism (AROA).

Table 2. Ocular Albinism Types (Open Table in a new window)

OA SubtypesGene PositionAffected Protein
OA 1 (X-linked recessive OA/Nettleshop-Falls type)X p22.3-22.2The protein product of the OA 1 gene named OA 1 (and also identified as GPR143 in GenBank)[2, 3]
AROANot a distinct positionTyrosinase in some cases;



P protein in some cases



Next

Pathophysiology

Melanin is a photoprotective pigment in the skin that absorbs UV light from the sun, thereby preventing skin damage. With sun exposure, the skin normally tans as a result of increased melanin pigment in the skin. However, many albinos are sensitive to sunlight and develop a sunburn because of the lack of melanin.

In addition to the skin, melanin is important to other areas of the body, such as the eyes and brain, although the function in these areas is not currently known.

Melanin in the eye

The eye has 2 origins from which pigmented cells are derived, as follows:

  • The neuroectoderm of the primitive forebrain is the origin of melanocytes in the retinal pigment epithelium, iris epithelium (anterior and posterior), and ciliary epithelium (outer pigmented and inner nonpigmented).
  • The neural crest is the origin of melanocytes in the iris stroma, ciliary stroma, and choroid. Melanoblasts from the neural crest migrate to the skin, inner ear, and uveal tract.

The presence of melanin during ocular development is important. The fovea fails to develop properly if melanin is absent during development. Other areas of the retina develop normally regardless of the presence of melanin. Additionally, neural connections between the retina and the brain are altered if melanin in the retina is absent during development. The amount of pigment necessary for appropriate ocular development is currently unknown. More research needs to be completed.

Melanin pathway

Melanin is formed in the melanosome organelle of the melanocyte. Melanocytes are found in the skin, hair follicles, and pigmented tissues of the eye. The melanin pathway consists of a series of reactions that converts tyrosine into 2 types of melanin, as follows: black-brown eumelanin and red-blond pheomelanin. Genetic mutations affecting proteins/enzymes along this pathway inevitably result in reduced melanin production.

Tyrosinase is the major enzyme (coded on chromosome 11) involved in the series of conversions to form melanin from tyrosine. It is responsible for converting tyrosine to DOPA and then to dopaquinone. Through a sequence of steps, dopaquinone subsequently is converted to either eumelanin or pheomelanin. Mutation to the tyrosinase enzyme produces either OCA 1 or AROA.

Additionally, 2 other enzymes involved in the formation of eumelanin are tyrosinase-related protein 1 (TRP1; DHICA oxidase) and tyrosinase-related protein 2 (TRP2; dopachrome tautomerase). Both of these enzymes are coded on chromosome 9. Mutation to the TRP1 gene causes OCA 3. Mutation to the TRP2 gene does not produce albinism.

Finally, P protein is a melanosomal membrane protein that is believed to be involved in the transport of tyrosine prior to melanin synthesis. Mutation to this P gene produces OCA 2.

Pathogenesis of ocular features

The development of the optic system is highly dependent on the presence of melanin. If melanin is absent or reduced, the ocular features appear. The mechanisms for these changes include the following:

  • Abnormal decussation of optic nerve fibers is due to misrouting of the retinogeniculate projections. It is postulated that melanin determines neuronal target specificity in the brain. Therefore, when pigmentation is incomplete, the developing optic tracts almost completely cross at the chiasm. In nonalbino persons, 45% of axons originating in the temporal half of the retina remain uncrossed as they pass through the chiasm and project to the ipsilateral lateral geniculate nucleus. Most of these fibers serve the central 20° of the temporal retina. However, in albino persons, most of the fibers decussate at the chiasm and synapse in the contralateral lateral geniculate nucleus. This leads to a predominance of monocular vision and decreased binocular depth perception.
  • Light scattering within the eye causes the sensation of photophobia and decreased visual acuity. The translucent irides cause increased light to enter the eye, resulting in light scattering. Patients typically have a supernormal electroretinography (ERG) recording.
  • Light-induced retinal damage has been postulated as a contributing mechanism to decreased visual acuity. With increased light scattering, it has been proposed that light-generated free radicals are responsible for nonthermal light damage to the retina. Additionally, it is believed that melanin may play a protective role in reducing these free radicals.
  • Foveal hypoplasia is the most significant factor causing decreased visual acuity. The macula lutea pigment is believed to be absent. Currently, the etiology of foveal hypoplasia is not completely known; however, it may be due to the decreased melanin in the retinal pigment epithelium (RPE).
  • Congenital nystagmus usually occurs in the first 3 months of life and may lead to the misdiagnosis of congenital motor nystagmus.
  • Light-induced subclinical damage to the corneal epithelium and its binding to the Bowman membrane have been postulated as a contributing mechanism to the decreased adhesion of the corneal epithelium in LASIK surgery, leading to a very high risk of epithelial abrasion during LASIK in patients with albinism. Possibly, the increased light scattering produces light-generated free radicals that are responsible for nonthermal light damage to the epithelial linking proteins. Additionally, it is believed that melanin may play a protective role in reducing these free radicals.
Previous
Next

Epidemiology

Frequency

United States

An estimated 1 in 17,000 people have one of the types of albinism. Approximately 18,000 people in the United States have albinism.

OCA 1 occurs in approximately 1 in 40,000 individuals in most populations.

OCA 2 is the most common type of albinism and is especially frequent among African Americans and Africans. The estimated frequency in African Americans is 1 case per 10,000 population, while in whites, the frequency is 1 case per 36,000 population. The overall frequency is 1 case per 15,000 population across all races.

Hermansky-Pudlak syndrome (HPS) s the most common type of albinism in Puerto Rico, with a frequency of 1 case per 2,700 population. This disorder is very rare in other parts of the world.

Mortality/Morbidity

  • Albinism is not associated with mortality. Lifespan is within normal limits. Because the reduction of melanin in the hair, skin, and eyes should have no systemic effects, the general health of a child and an adult with albinism is normal. The growth and intellectual development of a child with albinism should be normal, with developmental milestones expected for age.
  • The morbidity associated with albinism pertains to visual impairment, skin photosensitivity, and increased cutaneous cancer risk. Patients who have syndromes associated with albinism (eg, HPS) may have hearing difficulties or abnormalities of blood clotting. Albinism also has social ramifications because patients may feel alienated as a result of the difference in appearance from their families, peers, and other members of their ethnic group.

Race

  • Albinism affects all persons of races.
  • Parents of most children with albinism have normal eye color for their ethnic background.
  • A high incidence of HPS exists among Puerto Ricans.

Sex

  • Both males and females can be affected. However, in OA 1 (X-linked recessive OA), males are affected, while females are only carriers.

Age

  • All types of albinism are usually congenital.
Previous
 
 
Contributor Information and Disclosures
Author

Mounir Bashour, MD, CM, FRCS(C), PhD, FACS  Assistant Professor of Ophthalmology, McGill University; Clinical Assistant Professor of Ophthalmology, Sherbrooke University; Medical Director, Cornea Laser and Lasik MD

Mounir Bashour, MD, CM, FRCS(C), PhD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American College of International Physicians, American College of Surgeons, American Medical Association, American Society of Cataract and Refractive Surgery, American Society of Mechanical Engineers, American Society of Ophthalmic Plastic and Reconstructive Surgery, Biomedical Engineering Society, Canadian Medical Association, Canadian Ophthalmological Society, Contact Lens Association of Ophthalmologists, International College of Surgeons US Section, Ontario Medical Association, Quebec Medical Association, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Coauthor(s)

Khalid Hasanee, MD  Glaucoma and Anterior Segment Fellow, Department of Ophthalmology, University of Toronto

Khalid Hasanee, MD is a member of the following medical societies: Canadian Medical Association, Canadian Ophthalmological Society, and Ontario Medical Association

Disclosure: Nothing to disclose.

Iqbal Ike K Ahmed, MD, FRCSC  Clinical Assistant Professor, Department of Ophthalmology, University of Utah

Iqbal Ike K Ahmed, MD, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Canadian Ophthalmological Society, and Ontario Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Gerhard W Cibis, MD  Clinical Professor, Director of Pediatric Ophthalmology Service, Department of Ophthalmology, University of Kansas, Kansas City

Gerhard W Cibis, MD is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, and American Ophthalmological Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

J James Rowsey, MD  Former Director of Corneal Services, St Luke's Cataract and Laser Institute, Florida

J James Rowsey, MD is a member of the following medical societies: American Academy of Ophthalmology, American Association for the Advancement of Science, American Medical Association, Association for Research in Vision and Ophthalmology, Florida Medical Association, Pan-American Association of Ophthalmology, Sigma Xi, and Southern Medical Association

Disclosure: Nothing to disclose.

Lance L Brown, OD, MD  Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

References
  1. Summers CG. Albinism: classification, clinical characteristics, and recent findings. Optom Vis Sci. Jun 2009;86(6):659-62. [Medline].

  2. Schiaffino MV, Tacchetti C. The ocular albinism type 1 (OA1) protein and the evidence for an intracellular signal transduction system involved in melanosome biogenesis. Pigment Cell Res. Aug 2005;18(4):227-33. [Medline].

  3. Innamorati G, Piccirillo R, Bagnato P, Palmisano I, Schiaffino MV. The melanosomal/lysosomal protein OA1 has properties of a G protein-coupled receptor. Pigment Cell Res. Apr 2006;19(2):125-35. [Medline].

  4. Wang T, Waters CT, Jakins T, et al. Temperature sensitive oculocutaneous albinism associated with missense changes in the tyrosinase gene. Br J Ophthalmol. Oct 2005;89(10):1383-4. [Medline].

  5. Ramsay M, Colman MA, Stevens G, et al. The tyrosinase-positive oculocutaneous albinism locus maps to chromosome 15q11.2-q12. Am J Hum Genet. Oct 1992;51(4):879-84. [Medline].

  6. Brodsky MC, Fray KJ. Positive angle kappa: a sign of albinism in patients with congenital nystagmus. Am J Ophthalmol. Apr 2004;137(4):625-9. [Medline].

  7. Bradfield YS, France TD, Verhoeve J, Gangnon RE. Sweep visual evoked potential testing as a predictor of recognition acuity in albinism. Arch Ophthalmol. May 2007;125(5):628-33. [Medline].

  8. Dorey SE, Neveu MM, Burton LC, Sloper JJ, Holder GE. The clinical features of albinism and their correlation with visual evoked potentials. Br J Ophthalmol. Jun 2003;87(6):767-72. [Medline].

  9. Carden SM, Boissy RE, Schoettker PJ, Good WV. Albinism: modern molecular diagnosis. Br J Ophthalmol. Feb 1998;82(2):189-95. [Medline].

  10. Charles SJ, Green JS, Grant JW, Yates JR, Moore AT. Clinical features of affected males with X linked ocular albinism. Br J Ophthalmol. Apr 1993;77(4):222-7. [Medline].

  11. Creel D, Witkop CJ Jr, King RA. Asymmetric visually evoked potentials in human albinos: evidence for visual system anomalies. Invest Ophthalmol. Jun 1974;13(6):430-40. [Medline].

  12. Cullom RD, Chang B. Albinism. In: Wills Eye Manual: Office & Emergency Room Diagnosis & Treatment of Eye Disease. 2nd ed. Lippincott Williams & Wilkins: 1994:408-409.

  13. Garner A, Jay BS. Macromelanosomes in X-linked ocular albinism. Histopathology. May 1980;4(3):243-54. [Medline].

  14. Giebel LB, Tripathi RK, Strunk KM, et al. Tyrosinase gene mutations associated with type IB ("yellow") oculocutaneous albinism. Am J Hum Genet. Jun 1991;48(6):1159-67. [Medline].

  15. Kanski JJ. Albinism. Clin Ophthalmol. 1999;459-461.

  16. King RA, Hearing VJ, Creed DJ, Oetting WS. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. McGraw-Hill; 1995:4353-92.

  17. King RA, Pietsch J, Fryer JP, et al. Tyrosinase gene mutations in oculocutaneous albinism 1 (OCA1): definition of the phenotype. Hum Genet. Nov 2003;113(6):502-13. [Medline].

  18. King RA, Summers CG. Albinism. Dermatol Clin. Apr 1988;6(2):217-28. [Medline].

  19. King RA, Summers GC, Haefemeyer JW, LeRoy B. Facts About Albinism. [Full Text].

  20. Lee ST, Nicholls RD, Bundey S, Laxova R, Musarella M, Spritz RA. Mutations of the P gene in oculocutaneous albinism, ocular albinism, and Prader-Willi syndrome plus albinism. N Engl J Med. Feb 24 1994;330(8):529-34. [Medline].

  21. Oetting WS. The tyrosinase gene and oculocutaneous albinism type 1 (OCA1): A model for understanding the molecular biology of melanin formation. Pigment Cell Res. Oct 2000;13(5):320-5. [Medline].

  22. Oetting WS, Brilliant MH, King RA. The clinical spectrum of albinism in humans. Mol Med Today. Aug 1996;2(8):330-5. [Medline].

  23. Oetting WS, King RA. Molecular basis of oculocutaneous albinism. J Invest Dermatol. Nov 1994;103(5 Suppl):131S-136S. [Medline].

  24. Oetting WS, Summers CG, King RA. Albinism and the associated ocular defects. Metab Pediatr Syst Ophthalmol. 1994;17(1-4):5-9. [Medline].

  25. Spritz RA. Molecular genetics of oculocutaneous albinism. Semin Dermatol. Sep 1993;12(3):167-72. [Medline].

  26. Tomita Y. The molecular genetics of albinism and piebaldism. Arch Dermatol. Mar 1994;130(3):355-8. [Medline].

  27. Toyofuku K, Valencia JC, Kushimoto T, et al. The etiology of oculocutaneous albinism (OCA) type II: the pink protein modulates the processing and transport of tyrosinase. Pigment Cell Res. Jun 2002;15(3):217-24. [Medline].

  28. Traboulsi EI, Green WR, O'Donnel FE Jr. The eye in albinism. In: Duane's Clinical Ophthalmology. Vol 4. Lippincott-Raven; 1999:1-20.

  29. Witkop CJ Jr, Nance WE, Rawls RF, White JG. Autosomal recessive oculocutaneous albinism in man. Evidence for genetic heterogeneity. Am J Hum Genet. Jan 1970;22(1):55-74. [Medline].

  30. Zahed L, Zahreddine H, Noureddine B, et al. Molecular basis of oculocutaneous albinism type 1 in Lebanese patients. J Hum Genet. 2005;50(6):317-9. [Medline].

Previous
Next
 
Table 1. Oculocutaneous Albinism Types
OCA SubtypesGene PositionAffected Protein
OCA 1
  • OCA 1A (tyrosinase-negative OCA)
  • OCA 1B (yellow-mutant/Amish/
  • xanthous, temperature-sensitive)
  • OCA 1A/1B heterozygote
11q14-21Tyrosinase
OCA 2



(tyrosinase-positive OCA, brown OCA)



15q11-13P protein
OCA 39p23Tyrosinase-related protein
Table 2. Ocular Albinism Types
OA SubtypesGene PositionAffected Protein
OA 1 (X-linked recessive OA/Nettleshop-Falls type)X p22.3-22.2The protein product of the OA 1 gene named OA 1 (and also identified as GPR143 in GenBank)[2, 3]
AROANot a distinct positionTyrosinase in some cases;



P protein in some cases



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.